AML predominantly affects older individuals, who are often not suitable for intensive chemotherapy due to their age and pre-existing conditions. Younger patients may also be ineligible for intensive chemotherapy due to comorbidities or unfavorable genetic characteristics.1 Treatment with Venclyxto® + Aza was shown to be effective in this group of patients with newly diagnosed AML in the VIALE- A trial (NCT02993523).1 In the webcast, PD. Boris Schleiffenbaum, MD, presented the current study data and a patient case.
PD Dr. med. Boris Schleiffenbaum
Hematology and General Internal Medicine
Hirslanden Group
Dr. sc. nat. Katja Becker
This article was produced with the financial support of AbbVie AG, Alte Steinhauserstrasse 14, Cham.
CH-VNCAML-230008 04/2023
The brief technical information of Venetoclax®
Literature
1. DiNardo CD et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med, 2020. 383(7): p. 617-629.
The references can be requested by professionals at medinfo.ch@abbvie.com.
Post online since 08.05.2023
